A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001

Inclusion Criteria

• •Main Inclusion
• •Subject's written informed consent obtained prior to any study-related procedure
• •Male and female Caucasian healthy volunteers aged 18-55 years inclusive
• •Vital signs:Subjects aged 18-45: Diastolic BP 40-90, Systolic BP 90-140 Subjects aged 45-55: Diastolic BP 40-90, Systolic BP 90-150 (as mean of three measures performed after at least 5 minutes of resting); checked at screening visit and Day -1
• •12-lead digitised Electrocardiogram (12-lead ECG) considered as normal (40≤Heart rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms for females) checked at screening visit and Day -1
• •Lung function measurements within normal limits: FEV1 \> 80% of predicted normal value (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Values (1,2) ) and FEV1/FVC ratio \> 0.70
• •Main Exclusion:
• •Pregnant or lactating women
• •Clinically significant cardiac abnormalities
• •Any clinically relevant abnormal laboratory values